Molecular pathogenesis of chronic myeloid leukemia
- 01.12.2016
- short review
Erschienen in:
- Verfasst von
- Gerald Webersinke
- Erschienen in
- memo - Magazine of European Medical Oncology | Ausgabe 4/2016
Summary
Chronic myeloid leukemia (CML) is a paradigm for effective targeted therapy and is characterized by the hallmark BCR-ABL1 fusion. Although survival of affected patients has dramatically increased with the introduction of tyrosine kinase inhibitor therapy, kinase-dependent and -independent resistance mechanisms remain a problem and therefore new clinical strategies based on our growing knowledge of cellular processes are required. New diagnostic opportunities support this task and will change disease management in the future.
Anzeige
- Titel
- Molecular pathogenesis of chronic myeloid leukemia
- Verfasst von
-
Gerald Webersinke
- Publikationsdatum
- 01.12.2016
- Verlag
- Springer Vienna
- Erschienen in
-
memo - Magazine of European Medical Oncology / Ausgabe 4/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076 - DOI
- https://doi.org/10.1007/s12254-016-0294-0
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.